Validation and development of MTH1 inhibitors for treatment of cancer.
暂无分享,去创建一个
Y. Kallberg | P. Artursson | R. Zubarev | B. Seashore-Ludlow | T. Helleday | E. Homan | V. Gorgoulis | R. Jafari | Gianluca Maddalo | J. Lehtiö | T. Visnes | A. Chernobrovkin | U. W. Berglund | F. Gaugaz | A. Lindqvist | M. Scobie | T. Koolmeister | J. Nilsson | A. Jemth | C. Gokturk | K. Sanjiv | T. Pham | O. Loseva | B. Einarsdottir | P. Herr | R A Zubarev | P Artursson | L. Bräutigam | N. Schipper | I S Pateras | M Scobie | O. Wallner | I. Pateras | T Helleday | Anne M. Filppula | U Warpman Berglund | K Sanjiv | H Gad | C Kalderén | T Koolmeister | T Pham | C Gokturk | R Jafari | G Maddalo | B Seashore-Ludlow | A Chernobrovkin | A Manoilov | A Rasti | A-S Jemth | I Almlöf | O Loseva | T Visnes | B O Einarsdottir | F Z Gaugaz | A Saleh | B Platzack | O A Wallner | K S A Vallin | M Henriksson | P Wakchaure | S Borhade | P Herr | Y Kallberg | P Baranczewski | E J Homan | E Wiita | V Nagpal | T Meijer | N Schipper | S G Rudd | L Bräutigam | A Lindqvist | A Filppula | T-C Lee | J A Nilsson | V G Gorgoulis | J Lehtiö | Karl S. A. Vallin | B. Platzack | P. Baranczewski | S. G. Rudd | A. Filppula | K. Vallin | V. Nagpal | M. Henriksson | A. Saleh | T. Meijer | H. Gad | G. Maddalo | A. Rasti | U. Warpman Berglund | C. Kalderén | E. Wiita | Prasad Wakchaure | I. Almlöf | A. Manoilov | S. Borhade | T. Lee | P. Wakchaure | Paweł Baranczewski | Berglind O. Einarsdottir | Tobias Koolmeister | Elisée Wiita | Lars Bräutigam | Aljona Saleh | Alexey Chernobrovkin | Roman A Zubarev | A. Lindqvist | Per Artursson | Patrick Herr | Nicolaas G. M. Schipper | Jonas A. Nilsson
[1] Graeme Walker,et al. Potent and Selective Inhibitors of MTH1 Probe Its Role in Cancer Cell Survival. , 2016, Journal of medicinal chemistry.
[2] M. D. Topal,et al. DNA precursor pool: a significant target for N-methyl-N-nitrosourea in C3H/10T1/2 clone 8 cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[3] Richard Svensson,et al. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool , 2014, Nature.
[4] A. Egashira,et al. Analysis of MTH1 gene function in mice with targeted mutagenesis. , 2001, Mutation research.
[5] Marcela Dávila López,et al. Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions , 2014, Oncotarget.
[6] Horton,et al. Annals of Oncology , 1991, Springer US.
[7] F. Mseeh,et al. Identification of potent and selective MTH1 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.
[8] G. Superti-Furga,et al. Stereospecific targeting of MTH1 by (S)-crizotinib as anticancer strategy , 2014, Nature.
[9] G. Drewes,et al. Tracking cancer drugs in living cells by thermal profiling of the proteome , 2014, Science.
[10] Y. Yamagata,et al. Human MTH3 (NUDT18) Protein Hydrolyzes Oxidized Forms of Guanosine and Deoxyguanosine Diphosphates , 2012, The Journal of Biological Chemistry.
[11] P. Rai,et al. MTH1 counteracts oncogenic oxidative stress , 2015, Oncoscience.
[12] P. Nordlund,et al. The cellular thermal shift assay for evaluating drug target interactions in cells , 2014, Nature Protocols.
[13] J. Bartek,et al. The DNA-damage response in human biology and disease , 2009, Nature.
[14] Y. Pommier,et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. , 2012, Cancer research.
[15] M. Sekiguchi,et al. Mouse MTH2 protein which prevents mutations caused by 8-oxoguanine nucleotides. , 2003, Biochemical and biophysical research communications.
[16] A. Llombart‐Bosch,et al. Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] J. Stenvang,et al. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations , 2016, Journal of Experimental & Clinical Cancer Research.
[18] T. Helleday,et al. Hypoxic Signaling and the Cellular Redox Tumor Environment Determine Sensitivity to MTH1 Inhibition. , 2016, Cancer research.
[19] T. Helleday,et al. Crystal structure, biochemical and cellular activities demonstrate separate functions of MTH1 and MTH2 , 2015, Nature Communications.
[20] D. Nguyen,et al. MutT Homolog 1 (MTH1) maintains multiple KRAS-driven pro-malignant pathways , 2014, Oncogene.
[21] Makoto Muroi,et al. Proteomic profiling of small-molecule inhibitors reveals dispensability of MTH1 for cancer cell survival , 2016, Scientific Reports.
[22] Mark D. Johnson,et al. Birth of MTH1 as a therapeutic target for glioblastoma: MTH1 is indispensable for gliomatumorigenesis. , 2016, American journal of translational research.
[23] Thomas Helleday,et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.